FDA, Department Of Justice Seize Vail Products’ Hospital Beds
Vail Products' failure to inform FDA of adverse events related to its Vail 2000 enclosed beds contributed to a joint FDA and Department of Justice seizure of three of their models
More from Archive
More from Medtech Insight
The FDA staff cuts will probably mean longer device review times at least in the short term, speakers said at a recent webinar. But innovations like AI and third-party review could offer some hope, even as tariffs create a new set of problems.
Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.
Now that a federal judge has ruled the US FDA exceeded its authority by unilaterally assuming regulatory oversight of lab-developed tests, what’s the agency’s next move? And does it really have one?